BioSpace News Archive

Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced the first commercial use of its Tack Endovascular System® (4F) in multiple sites across the United States.

Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that financial results for the quarter ended March 31, 2020 will be released at 5:00 p.m. Eastern Time on Thursday, May 7, 2020.

Invacare Corporation (NYSE:IVC) (“Invacare” or the “company”) announces that it will release its financial results for the first quarter ended March 31, 2020, after the market closes on Wednesday, May 6, 2020. The company will provide a live conference call and webcast to discuss these financial results on Thursday, May 7, 2020 at 8:30 AM ET. Investors and other interested par

Vivera Pharmaceuticals, Inc., a California based pharmaceutical company has started nationwide delivery of its point of care, serological antibody rapid Covid-19 test kits.

Exogenesis announces today, the formation of nanoMesh LLC, a medical device company focused on commercialization of the Exogenesis Hernia Mesh (“nanoMesh”), an innovative soft tissue repair implant.

AdventHealth and CHI Franciscan Lead Three-Part Session with Data on Quality and Cost Improvements Achieved Through Electronic Glucose Management WALTHAM, Mass.--( BUSINESS WIRE )-- Glytec , the only provider of insulin management software across the continuum of care, announced today that AdventHealth and CHI Franciscan will lead a three-part session titled, “Computer-Guided Insulin Dosing” at the 2020 Diabetes Technology Society (DTS) Virtual

Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that its first quarter 2020 financial results will be released after market close on Thursday, May 7, 2020.

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI or the Company), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the pricing of its previously announced underwritten public offering of 45,454,545 common shares, at a public offering price of US$1.10 per share. VBI also granted the underwriters a 30-day option to purchase up to an additional 6

Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage company focused on discovering, developing and commercializing transformative therapies to treat rare and underserved ophthalmic diseases, today announced the amendment and exchange (the “Exchange”) of the Series A warrants issued pursuant to the Securities Purchase Agreement dated June 13, 2019 (“SPA”) with the holders of all outstanding Series A warrants.

Scientist.com, the healthcare industry’s leading marketplace for life science research, announced the launch of the COVID-19 Collaboration Center, a free website that brings together descriptions and links to research projects, laboratory services, reagents, funding sources, clinical trials and other resources that might help in the search for treatments, cures and vaccines for COVID-19.